Understanding AstraZeneca Share Prices and Performance

AstraZeneca's share price has been on a rollercoaster ride in recent years, with its stock value fluctuating based on various market and company-specific factors.

The company's share price has been influenced by its impressive pipeline of new medicines, including its COVID-19 vaccine, which has been a major contributor to its revenue growth.

AstraZeneca's share price has also been affected by its partnerships and collaborations, such as its deal with Oxford University to develop the COVID-19 vaccine.

The company's strong financial performance has led to a significant increase in its share price over the past few years, with its stock value more than doubling since 2017.

A different take: Astrazeneca Stock Symbol

AstraZeneca's valuation measures provide valuable insights into the company's financial health. Market capitalization stands at a significant 237.54 billion dollars.

The enterprise value of AstraZeneca is 263.27 billion dollars, indicating a substantial value beyond just the company's market capitalization. This is likely due to the company's strong financial performance and growth prospects.

The trailing P/E ratio of 28.73 suggests that investors are willing to pay a premium for AstraZeneca's shares, while the forward P/E ratio of 14.81 indicates a more reasonable valuation based on expected future earnings. This discrepancy could be a buying opportunity for investors.

AstraZeneca's PEG ratio of 0.88 suggests that the company's stock is undervalued compared to its growth prospects. This is a positive sign for investors looking to buy into the company.

Here are some key valuation metrics for AstraZeneca:

The enterprise value to revenue ratio of 4.66 suggests that AstraZeneca's revenue is generating a significant amount of value for the company. This is a positive sign for investors looking to invest in the company.

AstraZeneca's share price has seen a boost in recent times. The company's Q4 sales exceeded expectations, and its 2025 guidance was also higher than anticipated.

Their new lung cancer treatment has shown promising results, with a two-month improvement in survival rates. This is a significant development for the company and its investors.

AstraZeneca's stock performance can be tracked through the AZN stock ticker. If you're interested in keeping an eye on the company's progress, you can use this ticker to stay up-to-date.

Broaden your view: Ticker Symbol for Pfizer

AstraZeneca is 15.13% away from its 52-week high, which suggests that the stock has room to grow.

The company's promoters continue to hold a significant stake, with 75.00% of the shares remaining unchanged in the December 2024 quarter.

Looking at the management interviews, we can gain valuable insights into the company's strategies and future plans.

Here are some key points to consider:

It's worth noting that the promoters' holding has remained steady, indicating their confidence in the company's prospects.

Seasonality Analysis can be a valuable tool for investors and traders. AstraZeneca Pharma's historical data reveals some interesting trends.

In February, AstraZeneca Pharma has given negative returns in 13 out of 17 years. This suggests that February might not be the best month to invest in this company.

The data also shows that the average positive change in February is 17.63%, while the average negative change is -7.69%. This indicates that while there is potential for growth, there's also a higher risk of losses.

If this caught your attention, see: Why Do Share Prices Change

The maximum positive change in February was 26.64% in 2019, which is a significant increase. However, the maximum negative change was -30.01% in 2013, which is a substantial decline.

Here's a summary of the key statistics for February:

By understanding these seasonal patterns, investors can make more informed decisions and potentially avoid losses.

AstraZeneca has had a strong performance in the past few months, with a 1 month gain of 5.96% and a 3 month gain of 13.10%.

The company's stock has been on an upward trend, with a current year gain of 13.16%.

In the past week, AstraZeneca's stock has gained 0.49%.

Over the past month, the stock has increased by 5.96%.

Here's a summary of AstraZeneca's performance over different time periods:

The community sentiment on AstraZeneca's shares is overwhelmingly positive, with a 100% BUY rating and 0% SELL rating.

AstraZeneca's recent Q3 results have been met with enthusiasm, with one community member predicting that the stock could "blast and go 7900" if the result is positive.

The strong financial performance of AstraZeneca has been highlighted by a 44% increase in revenue, with total revenue from operations increasing by Rs 1345 Mn compared to the same period last year.

This positive outlook is echoed by another community member, who noted that the result is "very good" and that the stock could break its 52-week high if the market is positive.

The community is overwhelmingly bullish on AstraZeneca, with a 100% BUY sentiment.

There are no holds or sells, indicating a strong consensus among community members.

A user named abcd0987AstraZeneca predicts a positive market tomorrow, which could lead to a breakout above the 52-week high.

abcd0987AstraZeneca also mentions that if the result is positive, the stock could "blast" and reach 7900.

The community's enthusiasm is driven by the company's strong Q3 results, which showed a 44% increase in revenue compared to the same period last year.

Here's a summary of the community's sentiment:

Community and Broker Views often rely on the research done by brokers to make informed decisions.

Many brokers conduct thorough research on local markets, trends, and demographics to better understand their clients' needs.

According to a recent survey, 75% of brokers believe that understanding the local community is crucial for successful real estate transactions.

Brokers also rely on their network of contacts and relationships with other professionals to gather valuable insights and information.

Some brokers even go as far as to conduct their own market analysis, crunching numbers and creating reports to help them stay ahead of the curve.

In fact, a notable broker was quoted as saying, "I spend at least 2 hours a day researching and analyzing market trends to ensure I'm providing the best possible service to my clients."

In the past 6 months, AstraZeneca's share price has actually taken a hit, decreasing by 9.97%. This is a significant drop, and it's worth noting that it's the only negative return in the given timeframe.

The company's share price has been steadily increasing over the past 3 months, with a return of 13.10%. This suggests a strong upward trend in the company's performance.

Here's a breakdown of AstraZeneca's share price performance over different time periods:

The company's share price has been performing well over the past year, with a return of 13.16%. This suggests that the company is on a strong growth trajectory.

AstraZeneca's stock market performance has been impressive, with Q4 sales and 2025 guidance exceeding expectations. This is according to Pascal Soriot, the CEO of AstraZeneca.

The company's new lung cancer treatment has shown a two-month improvement in survival, which is a significant breakthrough in the field. Analysts are taking note of this development.

Here are some recent analyst recommendations for AstraZeneca:

UBS has also upgraded AstraZeneca to a Buy rating, which is a positive sign for investors.

AstraZeneca PLC has received positive analyst recommendations, with Bernstein maintaining a Buy rating on February 20. This is just one of the many upgrades the company has received recently.

UBS has upgraded AstraZeneca to a Buy rating, with the first upgrade happening on February 13, followed by another upgrade on the same day. This suggests a strong confidence in the company's future performance.

Here's a summary of the analyst recommendations:

These upgrades from reputable analysts demonstrate a growing confidence in AstraZeneca's ability to deliver strong results.

AstraZeneca's stock, AZN, has seen significant activity in the stock market, categorized under equities. This is evident from the recent news that exceeded expectations.

The company's CEO, Pascal Soriot, has made some promising statements about their new lung cancer treatment. This treatment shows a notable improvement in survival rates, specifically a two-month increase.

Pascal Soriot's comments about the treatment's potential are certainly optimistic, but it's essential to look at the numbers. The treatment's impact on survival rates is a significant development.

Here are some key points to consider:

The chart for AstraZeneca share prices is a valuable tool for investors. The close price of the security is adjusted on ex-date for Dividend, Bonus, Rights & Face Value Split.

The adjusted price is displayed when the security is undergoing a Corporate Action such as Dividend, Bonus, Rights or Face Value Split. This is because the %change is calculated with respect to the Adjusted Price on Corporate Action (Ex-date).

i-NAV (Indicative NAV) for an ETF is displayed as received from AMCs during each business day. This information is crucial for investors who want to keep track of the security's performance.

The close price will be updated after 18.15 hrs. This is to ensure that investors have the most up-to-date information.

Here are some key factors to consider when looking at the chart:

The dynamic price bands of 10% are applicable for securities in derivatives or securities included in indices on which derivative products are available. However, these bands may be relaxed intra-day in the event of a market trend in either direction.

Explore further: Icici Securities Share

AstraZeneca's share prices have been making headlines recently, and here are some of the latest updates:

Moody's has lifted AstraZeneca's ratings and revised its outlook to stable, which is a positive sign for investors.

AstraZeneca has also made a significant move by buying FibroGen's China unit for $160 million, giving it access to an anemia drug.

This acquisition is a strategic move by AstraZeneca to boost its presence in the Chinese market.

AstraZeneca's stock price has been affected by the mixed earnings of UK companies, which have weighed on the FTSE 100 for the third day in a row.

Here are some key updates on AstraZeneca's share prices:

AstraZeneca has also received a Buy rating from Bernstein, maintaining its positive outlook for the company.

The US CDC has postponed its vaccine advisory meeting, which could impact AstraZeneca's share prices if the meeting had been scheduled to discuss the company's vaccine.

The European equities traded in the US saw American Depositary Receipts edge higher in Thursday trading, which could be a positive sign for AstraZeneca's share prices.